Binding to the open conformation of HIV-1 protease

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 7, 2011, Pages 2282-2290

  Lexa, Katrina W ^a   Carlson, Heather A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AIDS; Drug design; Ligand binding; Molecular dynamics; Protein flexibility

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE ALPHA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE BETA; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION;

CRYSTALLIZATION; DRUG DESIGN; HIV PROTEASE; MODELS, CHEMICAL; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79958766155     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23054     Document Type: Article

References (29)

1. Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. Curr Pharm Des 2007; 13: 271-285.
2. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009; 69: 477-503.
3. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53: 521-538.
4. Hornak V, Simmerling C. Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today 2007; 12: 132-138.
5. Freedberg DI, Ishima R, Jacob J, Wang YX, Kustanovich I, Louis JM, Torchia DA. Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci 2002; 11: 221-232.
6. Ishima R, Freedberg DI, Wang YX, Louis JM, Torchia DA. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 1999; 7: 1047-1055.
7. Nicholson LK, Yamazaki T, Torchia DA, Grzesiek S, Bax A, Stahl SJ, Kaufman JD, Wingfield PT, Lam PY, Jadhav PK, Hodge CN, Domaille PJ, Chang C-H. Flexibility and function in HIV-1 protease. Nat Struct Biol 1995; 2: 274-280.
8. Sadiq AK, Wan S, Coveney PV. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site. Biochemistry 2007; 46: 14865-14877.
9. Rick SW, Erickson JW, Burt SK. Reaction path and free energy calculations of the transition between alternate conformations of HIV-1 protease. Proteins 1998; 32: 7-16.
10. Perryman AL, Lin JH, McCammon JA. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci 2004; 13: 1108-1123.
11. Böttcher J, Blum A, Dörr S, Heine A, Diederich WE, Klebe G. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors. ChemMedChem 2008; 3: 1337-1344.
12. Damm KL, Ung PM, Quintero JJ, Gestwicki JE, Carlson HA. A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 2008; 89: 643-652.
13. Meagher KL, Carlson HA. Solvation influences flap collapse in HIV-1 protease. Proteins:Struct Funct Genet 2005; 58: 119-125.
14. DeLano WL. The PyMOL molecular graphics system. Palo Alto, CA: DeLano Scientific; 2008.
15. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, 3rd, Snoeyink J, Richardson JS, Richardson DC. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007; 35(Web Server issue): W375-W383.
16. MOE. Montreal, Canada: Chemical Computing Group, Inc.; 2008.
17. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem 2004; 25: 1157-1174.
18. Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method. J Comput Chem 2000; 21: 132-146.
19. Case DA, Darden TA, Cheatham TE, III, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Wang B, Pearlman DA, Crowley M, Brozell S, Tsui V, Gohlke H, Mongan J, Hornak V, Cui G, Beroza P, Schafmeister C, Caldwell J, Ross W, Kollman P. AMBER 8. version 8. San Francisco, CA: University of California; 2004.
20. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926-935.
21. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: Application to microtubules and the ribosome. Proc Natl Acad Sci USA 2001; 98: 10037-10041.
22. Lerner M. APBS plugin. Ann Arbor, MI: University of Michigan; 2004.
23. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins:Struct Funct Genet 2006; 65: 712-725.
24. Darden T, York D, Pedersen L. Particle Mesh Ewald-an N.Log(N) method for Ewald Sums in large systems. J Chem Phys 1993; 98: 10089-10092.
25. Shao J, Tanner SW, Thompson N, Cheatham TE. Clustering molecular dynamics trajectories: I. Characterizing the performance of different clustering algorithms. J Chem Theory Comput 2007; 3: 2312-2334.
26. Davies DL, Bouldin DW. A cluster separation measure. Pattern analysis and machine intelligence. IEEE Trans on PAMI 1979; 1: 224-227.
27. Calinski T, Harabasz J. A dendrite method for cluster analysis. Commun Stat 1974; 3: 1-27.
28. Perryman AL, Zhang Q, Soutter HH, Rosenfield R, McRee DE, Olson AJ, Elder JE, Stout CD. Fragment-based screen against HIV Protease. Chem Biol Drug Des 2010; 75: 257-268.
29. Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 2005; 13: 1887-1895.